Indian regulator flags Abhayrab rabies vaccine batch over potency failure
India’s drug regulator has flagged Indian Immunologicals’ Abhayrab batch KE25012 as substandard and potentially spurious after a potency-test failure. State regulators have been asked to monitor distribution as packaging discrepancies trigger a counterfeit investigation.
What happened
Indian Immunologicals · India’s drug regulator flagged Abhayrab batch KE25012 as substandard and potentially spurious after potency-test failure, directing
Key facts
- Batch KE25012
- Batch KA24014
- Over 210 million Abhayrab doses supplied
- Approximately 40% of India's rabies vaccine market
- More than 20 years
- Exports to more than 40 countries
- Estimated 5,726 annual human rabies deaths in India
Why this matters
The incident highlights the strategic value of partners with strong biologics quality systems, serialization capabilities, and trusted cold-chain distribution in India’s vaccine market.
What to watch
- Formal recall, stop-sale, or seizure order from CDSCO or state drug regulators.
- Confirmation that the potency failure is isolated to KE25012 versus additional Abhayrab lots.
- Regulatory findings on whether the product is genuinely manufactured, falsified, diverted, or improperly stored.
- Reports of adverse events, vaccine failures, or patient notification requirements linked to the batch.
- Distributor-level supply interruptions, emergency procurement activity, or price increases for alternative rabies vaccines.
- Inspection notices, warning letters, or manufacturing restrictions involving Indian Immunologicals facilities.
- Immediately block, quarantine, and reconcile all inventory carrying batch KE25012 across pharmacy, hospital, clinic, and distributor locations.
- Require documented batch-level confirmation from distributors and restrict replenishment to authorized, traceable channels.
- Notify dispensing teams and vaccination centers to verify packaging, batch identifiers, and supplier invoices before administration or sale.
- Prepare substitute-product sourcing and allocation plans for rabies post-exposure prophylaxis demand, prioritizing high-volume emergency and travel-health channels.
- Monitor regulator communications and preserve chain-of-custody records for any suspect inventory, returns, or customer complaints.